Cibc Private Wealth Group, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Cibc Private Wealth Group, LLC
- $53.9 Billion
- Q3 2024
A detailed history of Cibc Private Wealth Group, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 15 shares of CRNX stock, worth $820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 934
98.39%
Holding current value
$820
Previous $41,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$344 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$341 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$322 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$271 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$244 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.94B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...